Elanco Animal Health Incorporated (elan)
ELAN — Company Overview
Investors tracking ELAN follow a Drug Manufacturers - Specialty & Generic name listed on NYQ within Healthcare.
| Ticker | ELAN |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NYQ |
| Market cap | $11.27B |
| Last price | $22.57 |
| Size category | Large Cap |
ELAN — Business Description
The business profile of Elanco Animal Health Incorporated (ELAN) reflects its role in Drug Manufacturers - Specialty & Generic. Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the…
Official website: https://www.elanco.com.
ELAN — Investment Thesis
Elanco Animal Health Incorporated (ELAN) attracts investors weighing Drug Manufacturers - Specialty & Generic fundamentals against current market pricing.
- Revenue is expanding at roughly 10.2% year-over-year (public data).
- Equity market capitalization is approximately $11.27B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
ELAN — Financial Health
ELAN financial profile reflects operating efficiency and capital structure using available market fundamentals.
Negative profit margin (-4.0%) signals near-term profitability pressure. Positive free cash flow of $826.88M supports balance-sheet flexibility.
| Forward P/E | 17.55× |
| Price / Sales | 2.25× |
| Price / Book | 1.71× |
| Gross margin | 55.4% |
| Operating margin | 8.6% |
| Profit margin | -4.0% |
| Return on equity | -3.0% |
| Debt / Equity | 64.25 |
| Free cash flow | $826.88M |
ELAN — Growth Outlook
Growth outlook for Elanco Animal Health Incorporated (ELAN) depends on demand trends in Drug Manufacturers - Specialty & Generic and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 10.2% indicates strong top-line momentum.
- Earnings growth of 4.4% year-over-year supports improving profitability.
- Price is 19.3% below the 52-week high.
- Shares trade 22.1% above the 52-week low — limited rebound so far.
ELAN — Competitive Position
Elanco Animal Health Incorporated (ELAN) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - Specialty & Generic.
- Market capitalization of $11.27B places ELAN among large-cap peers.
- Gross margin near 55.4% may reflect pricing power or favorable mix.
ELAN — Strengths
Strengths for Elanco Animal Health Incorporated (ELAN) inferred from public financial metrics:
- Revenue growth of 10.2% year-over-year.
- Earnings growth of 4.4% year-over-year.
- Gross margin of 55.4% supports competitive unit economics.
- Positive free cash flow ($826.88M).
- Moderate leverage (debt/equity 64.25).
- Large Cap scale ($11.27B) may provide distribution and funding advantages.
ELAN — Weaknesses
Weaknesses and pressure points for Elanco Animal Health Incorporated (ELAN) based on available data:
- Thin profit margin (-4.0%).
- High beta (1.68) amplifies market swings.
ELAN — Opportunities
- Sustained revenue growth (10.2%) could support multiple expansion if margins hold.
- Trading 22.1% above the 52-week low — potential recovery if fundamentals stabilize.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
ELAN — Risks
- Beta of 1.68 implies above-market volatility.
- Thin margins leave less room for operational missteps.
ELAN — Summary
Elanco Animal Health Incorporated (ELAN) is a large-cap Healthcare company focused on Drug Manufacturers - Specialty & Generic, listed on NYQ. Last price $22.57 with market cap $11.27B. Revenue grew 10.2% year-over-year per public data. Notable strengths include revenue growth of 10.2% year-over-year. Key watch items include thin profit margin (-4.0%). Review free estimates and earnings pages for ELAN; upgrade for institutional ownership and live headlines.
Start Free — open ELAN in Vest Terminal
Access live data, filings, ownership, and analysis for Elanco Animal Health Incorporated.
Elanco Animal Health Incorporated FAQ
What does Elanco Animal Health Incorporated (ELAN) do?
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks…
What is ELAN's P/E ratio?
Elanco Animal Health Incorporated has a trailing P/E of N/A× based on publicly available market data.
Does ELAN pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is ELAN in?
Elanco Animal Health Incorporated is classified in Healthcare (Drug Manufacturers - Specialty & Generic) on NYQ.
What is ELAN's market capitalization?
Approximate market cap: $11.27B.
What are the main risks for ELAN?
Key risks include above-average volatility (beta 1.68), among factors on this page.
What are the strengths of ELAN?
Potential positives include revenue growth of 10.2% year-over-year, earnings growth of 4.4% year-over-year.
Where can I get analyst estimates for ELAN?
Public analyst price targets and consensus for Elanco Animal Health Incorporated are on the free /stocks/elan/estimates page. Deeper estimate history and models are available in Vest Terminal.